tapebrief

MCHP · Q1 2026 Earnings

Bullish

Microchip Technology

Reported August 7, 2025

30-second summary

Microchip posted $1.08B in Q1 FY26 revenue, down 13.4% YoY but up 10.8% sequentially — the first real evidence that the two-year analog/MCU correction has bottomed. Management guided September to $1.13B (+5.1% QoQ) with gross margin stepping to 55–57% from 54.3%, and explicitly told investors the company will stop borrowing to fund the dividend after this quarter. Tone has shifted from defensive restructuring to quantifying the recovery mechanics — 77% incremental operating profit conversion, lead times bouncing off the bottom, July bookings the highest in three years.

Headline numbers

EPS

Q1 FY2026

$0.27

Revenue

Q1 FY2026

$1.08B

-13.4% YoY

Gross margin

Q1 FY2026

54.3%

Free cash flow

Q1 FY2026

$0.26B

Operating margin

Q1 FY2026

20.7%

Key financials

Q1 FY2026
MetricQ1 FY2026YoY
Revenue$1.08B-13.4%
EPS$0.27
Gross margin54.3%
Operating margin20.7%
Free cash flow$0.26B

Guidance

Prior quarter data unavailable — comparison not possible.

Capacity & utilization

Q1 FY2026
SegmentQ1 FY2026
Inventory Days on Balance Sheet214 days
Distribution Inventory Days29 days
Inventory Reduction$124.4 million

Profitability

Q1 FY2026
SegmentQ1 FY2026
Non-GAAP Operating Margin20.7%
Non-GAAP Gross Margin54.3%
Free Cash Flow Margin24.0%
Incremental Non-GAAP Gross Margin76%
Incremental Non-GAAP Operating Margin82%

Management tone

Management's posture has flipped from defensive restructuring narrative to actively quantifying recovery mechanics. Where prior quarters framed the inventory correction as a margin and revenue headwind requiring fab shutdowns and pay cuts, this print reframes the same inventory dynamic as a tailwind: "We are filling a supply chain deficit rather than experiencing any significant pull-forward activity... we expect the increase in gross margin percentage will continue as the inventory write-off continues to decrease." The same operational facts now point upward.

The lead-time commentary marks a clear regime change. For the past several quarters lead times sat stable at 4–8 weeks with ample capacity; this quarter management is openly telling investors that lead times are extending and supply chain capacity is being absorbed. "We are experiencing a lead time bounce off the bottom and increases on some of our products... we expect them to broaden and lead times go from the 4 to 8 weeks range to more like 6 to 10 weeks range." This is the first sign of pricing power returning to the channel, but it also raises the tail risk of repeating the PSP excess-inventory cycle — management addressed this preemptively, distinguishing current "scheduled backlog" requests from the prior non-cancellable PSP program.

Management aggressively rebutted the tariff-pull-in thesis that has dominated peer commentary. Rather than hedge, they quantified: tariff-related pull-ins were "mid to high single-digit millions" — roughly $7–9M of a $1.08B revenue base. This is the kind of specificity management uses when it wants to take a contrarian view off the table for investors, and it directly opposes the cautious framing from analog peers this earnings season.

The capital allocation message shifted from balance-sheet defense to durable capital return. "After this September quarter, we expect our adjusted free cash flow to exceed our dividend payment... we do not expect to have to borrow money to pay our dividend after this quarter." The dividend is no longer in question; excess cash flow goes to debt paydown. That is a meaningfully different message than the one Microchip delivered through the depth of the correction.

The emotional register also shifted. Management led with: "18,000 employees of Microchip worked all last year on a pay cut, have not received a bonus or a salary increase in a year and a half... came together to deliver an outstanding quarter." That is not a sentence a defensive management team writes. It signals confidence that recovery is durable enough to justify reinstating compensation, and quietly flags employee retention risk if recovery were to stall.

Recurring themes management leaned on this quarter:

Inventory normalization driving sequential revenue growth and margin recoveryDemand normalization from severely corrected baseline, not speculative buyingFactory utilization improving with ramp in December quarterLead time tightening as supply chain capacity constraints emergeAerospace/defense and AI data center as growth driversCash generation enabling dividend sustainability and debt reduction

Risks management surfaced:

Lead time pressures broadening from isolated areas to wider product portfolioSupply chain constraints on lead frames, substrates, and subcontracting capacityTariff-related order pull-ins may create demand normalization volatilityCustomer inventory management risk if backlog falls below 12-16 weeksPotential for speculative buying dynamics if lead times extend further

Q&A highlights

Chris Cazzo · Wolf Research

How far below end demand is the company shipping now, particularly for direct customers vs. distributors? Can you quantify undershipping?

Management acknowledges undershipping but declines to provide audit-proof numbers, citing data complexity (110,000+ customers, 26 global factories per customer, mixed inventory positions across products). Notes that during 'go-go days' direct customers received disproportionate shipments and likely built higher inventory than distributors, implying greater undershipping to direct customers today.

Cannot provide audit-proof quantification of undershippingDirect customers likely have higher excess inventory than distributors (from prior allocation preference)Customer base: 110,000+ customersInventory correction expected to continue for extended period

Blaine Curtis · Jefferies

Are lead time extensions (4-8 weeks to 6-10, 8-12 weeks) current or forward-looking? Why encourage customer orders if concerned about PSP-like dynamics?

Lead times currently extending on certain products/packages (6-10 weeks, some 8-12 weeks) due to lead frame, substrate, and subcontractor constraints. Management clarifies it's requesting scheduled backlog placement (not expediting), with fully cancelable orders and no rule changes—fundamentally different from PSP program. Largest monthly bookings in 3 years in July; backlog started September quarter stronger than June.

July bookings: largest month in prior 3 yearsCurrent lead times: 4-8 weeks broad base; 6-10 weeks and 8-12 weeks on specific productsSeptember quarter backlog stronger than June quarterOrders remain fully cancelable; no non-cancellable commitments

Timothy Arcuri · UBS

If bookings are highest in 3 years but guidance is only 5% sequential growth and turns are flat, doesn't this imply bookings are pulling into Q4/December rather than Q3/September? Should December be a 'good quarter'?

Management confirms that July bookings were strong and some portion is flowing into calendar Q4. September backlog is meaningfully higher than June backlog; with similar turns, expects 'good' September quarter (avoided defining 'good' with specific numbers). Reiterates expectation of above-seasonal growth in September, December, and March quarters.

September quarter backlog meaningfully higher than June quarter backlog (as of April 1 vs. July 1)Some strong bookings flowing into calendar Q4Terms requirement approximately same quarter-to-quarterExpects above-seasonal in September, December, and March

What to watch into next quarter

September gross margin within 55–57% guide range and incremental margin conversion above 70% — the entire bull case rests on operating leverage delivering as factory utilization ramps. A print at the low end with high underutilization charge would undermine the recovery thesis.

Inventory days reaching 195–200 by September quarter-end — management committed to this number explicitly. Slippage above 210 would signal demand is not recovering fast enough to absorb the burn-down pace.

Whether sell-through vs. sell-in gap closes further from $49.3M — convergence toward zero is the cleanest signal that distributor restocking is becoming end-demand-driven.

December guidance magnitude — does management commit to above-seasonal in dollar terms? — Arcuri's question went unanswered with specifics. If December comes in at or below 3% sequential, the "above-seasonal in three consecutive quarters" claim breaks.

Lead times stabilizing or extending beyond 6–10 weeks — extension toward 12+ weeks across broader product lines would raise PSP-repeat risk and likely force management to address speculative ordering directly.

Whether adjusted FCF actually exceeds the dividend in Q2 FY26 as promised — explicit commitment made on this print; the credibility of management's "stop borrowing to fund the dividend" message hinges on Q2 FCF clearing the common dividend run-rate (Q1 returned ~$245.5M to common stockholders via dividends per the press release).

Sources

  1. Microchip Technology Q1 FY2026 press release, exhibit 99.1, filed via SEC EDGAR — https://www.sec.gov/Archives/edgar/data/827054/000082705425000132/exhibit991q1fy26.htm
  2. Q&A content drawn from prepared analyst-call exchanges referenced in extraction inputs (Vivek Arya, Harsh Kumar, Chris Cazzo/Wolf Research, Blaine Curtis/Jefferies, Timothy Arcuri/UBS).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.